PacBio HiFi Sequencing Technology Will Be Used to Investigate Effect on Diagnostic Yield of Unresolved Rare Diseases in Children SINGAPORE and MENLO PARK, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) —…
MENLO PARK, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2021. Updates since our last…
MENLO PARK, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) — PacBio announced today that its executives will be speaking virtually at the following investor conferences: 11th Annual SVB Leerink Global Healthcare…
MENLO PARK, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year…
Hamilton Bonaduz AG announces first walk-away automation solution for PacBio’s High Molecular Weight DNA extraction technology BONADUZ, Switzerland, January 27, 2022 (BUSINESSWIRE) — Hamilton Bonaduz AG (“Hamilton”), a leading liquid…
MENLO PARK, Calif., Jan. 14, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s…
Industry Veteran Will Lead Company’s Commercial Growth Strategy in Americas Region MENLO PARK, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate,…
New Collaboration Builds on Existing Relationship Between the Two Companies to Develop Desktop Systems for the Clinical Market in China. Berry Genomics to Purchase at Least 50 Instruments at Product…
Pilot Project Designed to Demonstrate the Power of HiFi Sequencing to Effectively and Efficiently Identify Novel Variants Following Short-Read Genome Sequencing MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) —…
Initial Proof-of-Concept Work Suggests Strong Potential to Further Improve PacBio’s Highly Accurate HiFi Sequencing with Google Deep Learning Technologies MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ:…
MENLO PARK, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing platforms, today announced unaudited preliminary revenue of approximately $36.0 million…
Added Whole Genome Sequencing Capacity Enables the SOLVE-RD Research Program to Significantly Increase Sample Throughput MENLO PARK, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB), a leading developer…
PacBio’s Sequel IIe Devices Will Support Genomic Researchers Around the World MENLO PARK, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — PacBio (Nasdaq: PACB) today announced an expansion of its extensive…
The Study Will Evaluate the Impact of High-Resolution Genomes Generated on PacBio Technology in Studying Unsolved Rare Disease Cases MENLO PARK, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) — PacBio, a…
MENLO PARK, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) — PacBio announced today that its executives will be speaking virtually at the following investor conference: 40th Annual J.P. Morgan Healthcare Conference…
If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.